TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00532298

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's influenza vaccine GSK576389A [NH 2006/07 season]
Description: Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2006-2007 influenza season.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's influenza vaccine GSK576389A [NH 2006/07 season]
Description: Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2006-2007 influenza season.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's influenza vaccine GSK576389A [NH 2007/08 season]
Description: Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2007-2008 influenza season.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's influenza vaccine GSK576389A [NH 2007/08 season]
Description: Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2007-2008 influenza season.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix [NH 2006/07 season]
Description: Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix [NH 2007/08 season]
Description: Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
Study: NCT03282929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Part 1
Description: A single dose of 500 μg epinephrine (0.5 mL Suprarenin®) will be administered i.m. and s.c. by using a needle and a syringe in randomized order

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Part 2 Group 1
Description: 300 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 group 2
Description: 500 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Part 2 group 3
Description: 300 μg epinephrine auto-injector (Fastjekt, MEDA Pharma, 16 mm needle length)
Study: NCT02366546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
Study: NCT03282929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Part 2 Group 4
Description: 300 μg epinephrine auto-injector (Jext, Alk-Abelló, 15 mm needle length)
Study: NCT01811134

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PIPELINE flow diverter stent
Description: endovascular procedure using the medical device PIPELINE

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PIPELINE flow diverter stent
Description: endovascular procedure using the medical device PIPELINE

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coils, with or without expendable stent
Description: endovascular embolization procedure using microspires, with the possibility of using a balloon temporary and / or implantation of a stent complementary intracranial before implementation of microspires

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coils, with or without expendable stent
Description: endovascular embolization procedure using microspires, with the possibility of using a balloon temporary and / or implantation of a stent complementary intracranial before implementation of microspires
Study: NCT01771237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyPeeps Manualized Group Intervention
Description: Topics include: HIV/STI transmission, interpersonal communication, stigma management, condom use, substance use and risky sex, HIV-related harm reduction

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Sexual Health Education
Description: Topics include: HIV/STI transmission facts, myths regarding HIV transmission, information on effectiveness of condom use
Study: NCT02366546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1301 in combination with cyclophosphamide.
Study: NCT04355819

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disclosure timing
Description: When patients are told that a hernia was present on the CT scan

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disclosure timing
Description: When patients are told that a hernia was present on the CT scan
Study: NCT02366546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1301 in combination with cyclophosphamide.
Study: NCT03478800

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Each treatment would take approximately 15-20 minutes and would take place immediately after practice for a total of five treatments. The needles are standard (0.2mm diameter #36 gauge 1 inch stainless steel) and during each treatment, 3-6 needles would be placed in the lower extremity in any of the following muscle groups: quadriceps, hamstrings, anterior tibialis, gastrocnemius-soleus complex, medial head of the gastrocnemius, peroneal muscles, or iliotibial band. The athletes would complete brief pre- and post-treatment surveys.
Study: NCT00650403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine hydrochloride 40 mg tablet
Description: 40mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paxil® 40 mg Tablet
Description: 40mg, single dose fed
Study: NCT01391936

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tension Band Wiring
Description: AO technique of TBW for fixation of fracture.
Study: NCT01679990

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PLX-PAD high doses

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Double Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high dose +Placebo
Study: NCT00985114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoBarrier
Description: EndoBarrier implant

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet + Lifestyle Counseling
Description: Multidisciplinary lifestyle and nutritional counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet + Lifestyle Counseling
Description: Multidisciplinary lifestyle and nutritional counseling
Study: NCT01794221

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stitches and skin adhesive
Description: In addition to stitches, 2-octyl cyanoacrylate skin adhesive will be applied to the circumcision wound.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stitches only
Description: standard of care
Study: NCT02564627

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-applied patch
Description: An ambulatory self-applied patch will be placed weekly by the patients for PENS of dermatome T6.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional procedure
Description: PENS of dermatome T6 will be applied by the MD in the Outpatient Clinic.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: 1200 Kcal/day diet
Description: A 1200 Kcal/day diet will be prescribed.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1200 Kcal/day diet
Description: A 1200 Kcal/day diet will be prescribed.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1200 Kcal/day diet
Description: A 1200 Kcal/day diet will be prescribed.
Study: NCT01437982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol Etabonate
Description: Ocular administration of study drug. at least once within any indication of the label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Acetate 1% Oph Susp
Description: Ocular administration of study drug. at least once within any indication of the label.
Study: NCT01391936

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Plate fixation
Description: Patients in this arm will receive plate and screw fixation of their olecranon fracture.
Study: NCT02581735

Intervention type: OTHER
Intervention: Patients with haemophilia
Description: Using the platform Upatient, patients with hemophilia will register for one year, the prophylactic treatment who receive at home. Likewise, they indicate a replacement therapy as a result of joint bleeds.~At baseline, a month, 6 months and at the end of the study, patients shall complete two questionnaires. The same way in the initial evaluation and end of the study, the clinical joint status will be evaluated with HJHS scale .
Study: NCT04153526

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood samples will be obtained during routine clinical visits. Ideally, two 9mL blood samples (or equivalent volume) will be collected into EDTA or other appropriate blood collection tube at each time point except at baseline, where three EDTA 9mL tubes and one of 2.6mL (for study of whole blood) will be collected.

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood samples will be obtained during routine clinical visits. Ideally, two 9mL blood samples (or equivalent volume) will be collected into EDTA or other appropriate blood collection tube at each time point except at baseline, where three EDTA 9mL tubes and one of 2.6mL (for study of whole blood) will be collected.
Study: NCT01663064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (Zenith® p-Branch™ endovascular graft)
Description: Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
Study: NCT02298400

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acuvue® Oasys® Lenses (senofilcon A)
Description: Contact lenses placed in each eye during the day for about 8 hours

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acuvue® Oasys® Lenses (senofilcon A)
Description: Contact lenses placed in each eye during the day for about 8 hours

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acuvue® Oasys® Lenses (senofilcon A)
Description: Contact lenses placed in each eye during the day for about 8 hours

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 30-Day Bausch + Lomb PureVision (balafilcon A)
Description: Contact lenses placed in each eye during the day for about 8 hours

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 30-Day Bausch + Lomb PureVision (balafilcon A)
Description: Contact lenses placed in each eye during the day for about 8 hours

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 30-Day Bausch + Lomb PureVision (balafilcon A)
Description: Contact lenses placed in each eye during the day for about 8 hours

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clariti® 1-Day (Somofilcon A)
Description: Contact lenses placed in each eye during the day for about 8 hours
Study: NCT01726829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD-Logic Artificial Pancreas (MDLAP) system

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sensor augmented pump therapy
Study: NCT02298400

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clariti® 1-Day (Somofilcon A)
Description: Contact lenses placed in each eye during the day for about 8 hours

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clariti® 1-Day (Somofilcon A)
Description: Contact lenses placed in each eye during the day for about 8 hours
Study: NCT01805479

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: the active arm will be asked to perform 60% of maximum heart rate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: stretching and flexibility program
Description: stretching and flexibility program for the Placebo Comparator Arm
Study: NCT02630511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Mannitol consists of inhaling 0 (empty capsule acting as a placebo), 5, 10, 20, 40, 80, 160, 160, and 160 mg mannitol, resulting in a maximum cumulative dose of 635 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Mannitol consists of inhaling 0 (empty capsule acting as a placebo), 5, 10, 20, 40, 80, 160, 160, and 160 mg mannitol, resulting in a maximum cumulative dose of 635 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methacholine
Description: Methacholine consists of inhaling 0.0625 mg/mL, 0.25 mg/mL, 1 mg/mL, 4 mg/mL, and 16 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methacholine
Description: Methacholine consists of inhaling 0.0625 mg/mL, 0.25 mg/mL, 1 mg/mL, 4 mg/mL, and 16 mg/mL
Study: NCT04153526

Intervention type: PROCEDURE
Intervention: Surplus Tumour Tissue sample collection from surgery
Description: In surgical patients, lung tumour samples and normal lung tissue will be obtained from surplus tissue removed at the time of surgery. No extra procedures (biopsies or surgeries) are requested for the study.

Intervention type: OTHER
Intervention: Collection or archival tumour tissue (If available)
Description: Where available surplus tumour and normal tissue from archival tissue will be collected for analysis.

Intervention type: OTHER
Intervention: Collection or archival tumour tissue (If available)
Description: Where available surplus tumour and normal tissue from archival tissue will be collected for analysis.
Study: NCT02274363

Intervention type: OTHER
Intervention: No Intervention
Description: Participants will not receive any intervention in this study. Participants with chronic plaque type psoriasis will be assessed at a single time point, primarily for severity of plaque-type psoriasis Participants will not be followed over time. Data will be collected from the medical consultation notes, medical records and during interviews.
Study: NCT03429894

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: Drug eluting stent implant
Study: NCT01853319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73- 4506)
Description: 160 mg regorafenib per oral every day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
Study: NCT01821001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Bromocriptine
Description: Patients will receive 2.5 mg of vaginal bromocriptine tablet twice a day for the intervention. This will be administered for 6 months.
Study: NCT02630511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo consists of inhaling humidified air

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo consists of inhaling humidified air

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT01805843

Intervention type: OTHER
Intervention: Echo, exercise echo, and if indicated, right heart catheter
Description: routine echocardiography and special measurements of the right heart are performed at rest and during exercise
Study: NCT04352101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion XL
Description: Participants will take 150 milligrams per day (mg/d) of bupropion XL for two weeks, then the dose will be increased to 300mg/d, as tolerated, for the remaining 6 weeks of the study.
Study: NCT02489942

Intervention type: DRUG
Intervention: Jardiance
Description: Empagliflozin
Study: NCT00694902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK610677
Description: GSK610677 Multi-Dose Powder Inhaler will be available in the strength of 10, 50, 100 and 25 microgram with dose levels of 10, 30, 50, 100, 250, 500 and 1000 microgram. Subjects will receive GSK610677 as single inhale dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK610677
Description: GSK610677 Multi-Dose Powder Inhaler will be available in the strength of 10, 50, 100 and 25 microgram with dose levels of 10, 30, 50, 100, 250, 500 and 1000 microgram. Subjects will receive GSK610677 as single inhale dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK610677
Description: GSK610677 Multi-Dose Powder Inhaler will be available in the strength of 10, 50, 100 and 25 microgram with dose levels of 10, 30, 50, 100, 250, 500 and 1000 microgram. Subjects will receive GSK610677 as single inhale dose.
Study: NCT00554671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self efficacy
Description: Patients are taught with self-monitoring skills for diabetes and blood pressure, as well as healthy cooking and practiced under supervision
Study: NCT03569371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB054707
Description: INCB054707 administered once daily orally with water without regard to food for 8 weeks.
Study: NCT01791738

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acetabular positioning system
Description: Pre-operative planning through 3D software with design and fabrication of patient specific instruments for placement of a guide pin to be used to aid in bone preparation for insertion of an acetabular cup in total hip arthroplasty
Study: NCT04114253

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Study: NCT03422341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparison between GenePOC CR and Reference Method
Description: The collected swab will be tested with both the GenePOC Strep A, C/G assay and the Reference Method defined as standard microbiology culture and strain identification using a MALDI TOF.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison between GenePOC CR and Reference Method
Description: The collected swab will be tested with both the GenePOC Strep A, C/G assay and the Reference Method defined as standard microbiology culture and strain identification using a MALDI TOF.
Study: NCT01879228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.
Study: NCT00694902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK610677
Description: GSK610677 Multi-Dose Powder Inhaler will be available in the strength of 10, 50, 100 and 25 microgram with dose levels of 10, 30, 50, 100, 250, 500 and 1000 microgram. Subjects will receive GSK610677 as single inhale dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo for GSK610677 will be available as Multi-Dose Powder Inhaler. Subjects will receive Placebo as single inhale dose.
Study: NCT01879228

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.
Study: NCT01468766

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised progressive resistance training
Description: 2x60 minutes per week for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised progressive muscle relaxation training (Jacobson method)
Description: 2x60 minutes per week for 12 weeks
Study: NCT04780386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1805
Description: orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-1805-R1and NVP-1805-R2
Description: orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4)
Study: NCT00694902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo for GSK610677 will be available as Multi-Dose Powder Inhaler. Subjects will receive Placebo as single inhale dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo for GSK610677 will be available as Multi-Dose Powder Inhaler. Subjects will receive Placebo as single inhale dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo for GSK610677 will be available as Multi-Dose Powder Inhaler. Subjects will receive Placebo as single inhale dose.
Study: NCT00668603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17-b-estradiol
Description: 2mg oral daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17-b-estradiol
Description: 2mg oral daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17-b-estradiol + medroxyprogeterone acetate
Description: 2mg E2 + 5mg MPA daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17-b-estradiol + medroxyprogeterone acetate
Description: 2mg E2 + 5mg MPA daily for 6 months
Study: NCT00721695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS302
Description: OMS302 Irrigation Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OMS302-PE
Description: OMS302-PE HCI Irrigation Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Standard topical mydriatics and Balanced Salt Solution Irrigation Solution